Technical Analysis for DCTH - Delcath Systems, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Walk | Strength | 1.92% | |
| Wide Bands | Range Expansion | 1.92% | |
| Overbought Stochastic | Strength | 1.92% | |
| Upper Bollinger Band Walk | Strength | -1.77% | |
| Inside Day | Range Contraction | -1.77% | |
| Wide Bands | Range Expansion | -1.77% | |
| Overbought Stochastic | Strength | -1.77% |
| Alert | Time |
|---|---|
| Possible NR7 | about 3 hours ago |
| Possible Inside Day | about 3 hours ago |
| Up 3% | about 8 hours ago |
| Up 2% | about 8 hours ago |
| Up 1% | about 8 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Development Oncology Chemotherapy Chloride Melanoma Specialty Drugs Carcinoma Hepatology Liver Cancer Cholangiocarcinoma Interventional Oncology Intrahepatic Cholangiocarcinoma Ocular Melanoma
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Development Oncology Chemotherapy Chloride Melanoma Specialty Drugs Carcinoma Hepatology Liver Cancer Cholangiocarcinoma Interventional Oncology Intrahepatic Cholangiocarcinoma Ocular Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.88 |
| 52 Week Low | 2.84 |
| Average Volume | 385,919 |
| 200-Day Moving Average | 7.71 |
| 50-Day Moving Average | 10.06 |
| 20-Day Moving Average | 10.52 |
| 10-Day Moving Average | 11.14 |
| Average True Range | 0.67 |
| RSI (14) | 60.00 |
| ADX | 31.28 |
| +DI | 33.34 |
| -DI | 12.18 |
| Chandelier Exit (Long, 3 ATRs) | 10.86 |
| Chandelier Exit (Short, 3 ATRs) | 10.89 |
| Upper Bollinger Bands | 12.48 |
| Lower Bollinger Band | 8.56 |
| Percent B (%b) | 0.79 |
| BandWidth | 37.23 |
| MACD Line | 0.46 |
| MACD Signal Line | 0.29 |
| MACD Histogram | 0.1681 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.20 | ||||
| Resistance 3 (R3) | 12.18 | 11.99 | 12.11 | ||
| Resistance 2 (R2) | 11.99 | 11.85 | 11.99 | 12.08 | |
| Resistance 1 (R1) | 11.82 | 11.76 | 11.90 | 11.83 | 12.05 |
| Pivot Point | 11.62 | 11.62 | 11.66 | 11.63 | 11.62 |
| Support 1 (S1) | 11.45 | 11.48 | 11.54 | 11.47 | 11.25 |
| Support 2 (S2) | 11.26 | 11.40 | 11.26 | 11.22 | |
| Support 3 (S3) | 11.09 | 11.26 | 11.19 | ||
| Support 4 (S4) | 11.10 |
